Inflammasomes are multiprotein complexes formed and activated after exposure to different danger signals that lead to the maturation of caspase-1 and the processing of its substrates, IL-1β and IL-18. In recent years, the implication of different inflammasomes, especially NLRP3, in pulmonary, cardiovascular, hepatic, articular, neurodegenerative, psychiatric, and metabolic diseases has opened the door to developing new therapeutic perspectives. The NLRP3 is the best-described inflammasome and has also been involved in metabolic diseases such as obesity, diabetes, gout, atherosclerosis, and different metabolic biomarkers have been associated with the NLRP3 activation such as cholesterol, glucose, or fatty acids. Furthermore, metabolic derivative compounds such as itaconate or NAD may modulate the NLRP3 inflammasome complex, opening a new way for the design of metabolically tolerable inflammasome inhibitors.
This Research Topic aims to improve knowledge on the implication of the inflammasomes in the metabolism to identify therapeutic targets and inhibitors. We welcome the submission of original research and review articles covering a broad range of aspects related to the role of the inflammasome in the metabolism and pathophysiological aspect of the inflammasomes in diseases. This may include topics related to cardiovascular diseases, diabetes, gout, obesity, NASH, COPD and fibrosis and other metabolic disorders. We encourage the submission or articles that cover, but are not limited to, the following sub-topics:
• Inflammasomes activation in the lung response to pollution and allergens
• Inflammasomes in liver, cardiovascular and endocrinological diseases
• Inflammasomes and nutrition
• Inflammasomes and Inflammaging
• Neuroendocrine regulation of inflammasomes
• Metabolic and pharmacological inhibitors of inflammasomes
• Potential metabolic inducers of the inflammasome activation
• New insight into the NLRP3 pathway including GSDMD activation
• Crosstalk with the DNA sensing pathways
Topic Editor Gabriel Mbalaviele is a consultant for Aclaris Therapeutics, Inc., and holds stocks in the company. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Inflammasomes are multiprotein complexes formed and activated after exposure to different danger signals that lead to the maturation of caspase-1 and the processing of its substrates, IL-1β and IL-18. In recent years, the implication of different inflammasomes, especially NLRP3, in pulmonary, cardiovascular, hepatic, articular, neurodegenerative, psychiatric, and metabolic diseases has opened the door to developing new therapeutic perspectives. The NLRP3 is the best-described inflammasome and has also been involved in metabolic diseases such as obesity, diabetes, gout, atherosclerosis, and different metabolic biomarkers have been associated with the NLRP3 activation such as cholesterol, glucose, or fatty acids. Furthermore, metabolic derivative compounds such as itaconate or NAD may modulate the NLRP3 inflammasome complex, opening a new way for the design of metabolically tolerable inflammasome inhibitors.
This Research Topic aims to improve knowledge on the implication of the inflammasomes in the metabolism to identify therapeutic targets and inhibitors. We welcome the submission of original research and review articles covering a broad range of aspects related to the role of the inflammasome in the metabolism and pathophysiological aspect of the inflammasomes in diseases. This may include topics related to cardiovascular diseases, diabetes, gout, obesity, NASH, COPD and fibrosis and other metabolic disorders. We encourage the submission or articles that cover, but are not limited to, the following sub-topics:
• Inflammasomes activation in the lung response to pollution and allergens
• Inflammasomes in liver, cardiovascular and endocrinological diseases
• Inflammasomes and nutrition
• Inflammasomes and Inflammaging
• Neuroendocrine regulation of inflammasomes
• Metabolic and pharmacological inhibitors of inflammasomes
• Potential metabolic inducers of the inflammasome activation
• New insight into the NLRP3 pathway including GSDMD activation
• Crosstalk with the DNA sensing pathways
Topic Editor Gabriel Mbalaviele is a consultant for Aclaris Therapeutics, Inc., and holds stocks in the company. All other Topic Editors declare no competing interests with regards to the Research Topic subject.